jcm-logo

Journal Browser

Journal Browser

Diagnoses and Treatments of Juvenile and Rheumatoid Arthritis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: closed (31 December 2024) | Viewed by 1490

Special Issue Editor


E-Mail Website
Guest Editor
Past Director Internal Medicine and Gastroenterology, Internal Medicine and Medical therapy, Immune-Rheumatology Divisions, Director Department of Dermatologic, Immuno-Rheumatologic, Nephrologic and Urologic Sciences—IRCSS Policlinico Gemelli, 00168 Rome, Italy
Interests: diffuse scleroderma; rheumatoid arthritis; systemic sclerosis; arthritis; rheumatology, biomarkers and prognostic indexes in rheumatoid arthritis; autoimmune rheumatic diseases

Special Issue Information

Dear Colleagues,

Inflammatory arthritides affect kids and adults worldwide and represent key disabling illnesses when diagnosed and treated lately in the disease course. The outcome changes when diagnosed and treated very early on. In pediatric age, inflammatory arthritis presents a prevalence of JIA ranging from 3.8 to 400/100,000, with an incidence of 1.6 to 23/100,000 kids. The differences rely on the existence of at least five subtypes, each with a different pathophysiology and, therefore, a possible different therapeutic strategy.

In the adult age range, prevalence ranges between 14 and 36/100,000, with an incidence of 22/100,000 that doubles in the First Nations in North America. The great discovery of the last thirty years has been the availability of new drugs and the demonstration that, when used early on after diagnosis, the control of inflammation and bone-joint damage can lead to full or satisfactory remission with a pretty full maintenance of daily living activities. There are at least four subsets of the disease (seropositive, seronegative, RA in the elderly, and the difficult-to-treat subsets) that deserve specific attention because diagnosis and treatment may be particularly problematic. All these topics will be deeply covered in the coming Special Issue,which will describe the achievements obtained so far and the unmet needs that still need to be defined.

Prof. Dr. Gianfranco Ferraccioli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diffuse scleroderma
  • lupus nephritis
  • rheumatoid arthritis
  • systemic sclerosis
  • arthritis
  • rheumatology
  • juvenile arthritis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

23 pages, 799 KiB  
Review
Health-Related Quality of Life in Juvenile Idiopathic Arthritis: A Systematic Review of Phase III Clinical Trials
by Federica Romano, Federica Di Scipio, Giacomo Baima, Francesco Franco, Mario Aimetti and Giovanni Nicolao Berta
J. Clin. Med. 2025, 14(1), 254; https://doi.org/10.3390/jcm14010254 - 3 Jan 2025
Cited by 1 | Viewed by 1151
Abstract
Background/objectives: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood, leading to severe disability and negatively affecting patients’ health-related quality of life (HRQoL). The aim of this systematic review was to evaluate the adoption, reporting and assessment methodology of HRQoL [...] Read more.
Background/objectives: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood, leading to severe disability and negatively affecting patients’ health-related quality of life (HRQoL). The aim of this systematic review was to evaluate the adoption, reporting and assessment methodology of HRQoL in phase III clinical trials involving children with JIA. Methods: An electronic and manual search was conducted to identify primary and secondary publications of pharmacological trials conducted between 2012 and 2023. Data were extracted and recorded in duplicate. Results: A total of 222 studies were screened and 24 articles (22 primary and 2 secondary publications) were included in the review. HRQoL was not listed among the endpoints in 10 trials (45.5%), while it was a secondary endpoint in 12 trials (54.5%). The proportion of trials that did not consider HRQoL was equally relevant in both for-profit and no-profit settings (44.4% versus 50.0%), but it was higher in studies on systemic JIA compared to other JIA subtypes (62.5%), and on IL inhibitor treatment (72.7%) with respect to other disease-modifying antirheumatic drugs. Information on HRQoL was usually collected from parents/caregivers, and only three studies were categorized as “probably robust” with regard to HRQoL assessment. Conclusions: Systematic incorporation of HRQoL measures represents an urgent need in pediatric rheumatology, aiding clinicians in their decision-making in relation to treatment effectiveness and considering the children’s perspective. Full article
(This article belongs to the Special Issue Diagnoses and Treatments of Juvenile and Rheumatoid Arthritis)
Show Figures

Figure 1

Back to TopTop